Brokerages Anticipate Pieris Pharmaceuticals Inc (PIRS) Will Announce Earnings of -$0.17 Per Share

Wall Street brokerages expect that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will report earnings of ($0.17) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.19). Pieris Pharmaceuticals posted earnings per share of $0.17 during the same quarter last year, which would suggest a negative year over year growth rate of 200%. The company is expected to issue its next quarterly earnings report on Friday, March 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.49) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to ($0.44). For the next year, analysts expect that the firm will post earnings of ($0.77) per share, with EPS estimates ranging from ($0.95) to ($0.59). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. The business had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.16 million.

PIRS has been the subject of several analyst reports. BidaskClub upgraded shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. HC Wainwright set a $12.00 target price on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $10.00.

PIRS opened at $3.56 on Friday. Pieris Pharmaceuticals has a 1 year low of $3.24 and a 1 year high of $9.75. The firm has a market capitalization of $236.67 million, a P/E ratio of -8.90 and a beta of 1.94.

In other news, Director Christopher P. Kiritsy bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The stock was purchased at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $51,100. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 5.07% of the company’s stock.

A number of large investors have recently bought and sold shares of PIRS. Aquilo Capital Management LLC acquired a new position in Pieris Pharmaceuticals during the second quarter worth $10,013,000. BlackRock Inc. raised its position in Pieris Pharmaceuticals by 49.1% during the second quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock worth $13,616,000 after acquiring an additional 884,348 shares during the period. Prosight Management LP raised its position in Pieris Pharmaceuticals by 141.2% during the second quarter. Prosight Management LP now owns 1,360,000 shares of the biotechnology company’s stock worth $6,895,000 after acquiring an additional 796,237 shares during the period. Acadian Asset Management LLC raised its position in Pieris Pharmaceuticals by 45.5% during the second quarter. Acadian Asset Management LLC now owns 2,124,873 shares of the biotechnology company’s stock worth $10,773,000 after acquiring an additional 664,032 shares during the period. Finally, American Century Companies Inc. raised its position in Pieris Pharmaceuticals by 1,182.4% during the second quarter. American Century Companies Inc. now owns 467,779 shares of the biotechnology company’s stock worth $2,372,000 after acquiring an additional 431,302 shares during the period. Institutional investors own 65.26% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Recommended Story: Diversification in Your Portfolio

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply